Barboval oral drops bottle 25 ml

Pharmacodynamics. Barboval is a combined drug, the therapeutic effect of which is due to the pharmacological properties of its components.

Ethyl ester of α-bromizovaleric acid has a reflex, sedative and antispasmodic effect, due to a decrease in reflex excitability in the central nervous system and an increase in inhibition processes in the neurons of the cortex and subcortical structures of the brain, as well as a decrease in the activity of central vascular centers and a local direct antispasmodic effect on smooth muscles.

Phenobarbital inhibits the activating effect of the centers of the reticular formation of the medulla oblongata on the cerebral cortex, thereby reducing the flow of excitatory influences on the cerebral cortex and subcortical structures. Reducing the activating effects has (depending on the dose) a calming, tranquilizing and hypnotic effect. Barboval reduces the excitatory effect on the vasomotor centers, coronary and peripheral vessels, reducing overall blood pressure, eliminating and preventing vascular spasms, especially cardiac.

Menthol in the menthyl ester of isovaleric acid has a calming effect on the central nervous system, slows down the peristalsis of the stomach and intestines, reduces flatulence, and also has a moderate reflex vasodilator and antispasmodic effect.

Neuroses accompanied by increased excitability, insomnia, hysteria; as part of the complex treatment of mild attacks of angina pectoris, early stage angina, tachycardia of functional genesis, with stomach and intestinal spasms, and flatulence.

Barboval should be taken orally with a small amount of liquid or on a piece of sugar under the tongue.

The dosage and duration of treatment are determined by the doctor individually. Usually, adults take 10-15 drops 2-3 times a day for 10-15 days.

It is best to take the drug 20-30 minutes before meals.

After a break of 10-15 days, the course of treatment can be repeated.

Hypersensitivity to any component of the drug, hepatic and renal failure, hepatic porphyria, severe heart failure, severe arterial hypotension, acute myocardial infarction, diabetes mellitus, depression, myasthenia gravis, alcoholism, drug and medication addiction, respiratory diseases with shortness of breath, obstructive syndrome.

The drug is usually well tolerated. The following adverse reactions may develop:

from the digestive system: constipation, feeling of heaviness in the epigastric region, with prolonged use – impaired liver function, nausea, vomiting;

from the nervous system: weakness, ataxia, impaired coordination of movements, nystagmus, hallucinations, paradoxical excitement, decreased concentration, fatigue, slowed reactions, headache, cognitive impairment, confusion, drowsiness, mild dizziness;

from the side of the hematopoietic organs: anemia, thrombocytopenia, agranulocytosis;

Cardiovascular system: hypotension, bradycardia; immune system: hypersensitivity reactions, including angioedema, allergic reactions including skin rashes, itching, urticaria;

Skin and mucous membranes: Stevens-Johnson syndrome, toxic epidermal necrolysis;

from the musculoskeletal system: with prolonged use of drugs containing phenobarbital, there is a risk of osteogenesis disorders;

other: difficulty breathing.

Prolonged use of bromine-containing drugs can lead to bromine poisoning, which is characterized by the following symptoms: CNS depression, depressed mood, confusion, ataxia, apathy, conjunctivitis, rhinitis, lacrimation, acne, or purpura.

The presence of phenobarbital in the composition of the drug may lead to the risk of developing Stevens-Johnson and Lyell syndrome, which is most likely in the first weeks of treatment. Long-term use is not recommended due to the risk of developing drug dependence, possible accumulation of bromine in the body and the development of bromine poisoning. In cases where pain in the heart area does not go away after taking the drug, you should consult a doctor to rule out acute coronary syndrome. The drug should be prescribed with caution in cases of arterial hypotension, hyperkinesia, hyperthyroidism, adrenal hypofunction, acute and constant pain, acute drug intoxication.

Use during pregnancy or breastfeeding. The drug should not be used by women during pregnancy or breastfeeding.

The ability to influence the reaction rate when driving or operating other mechanisms. The drug may cause drowsiness and dizziness, therefore, during the period of treatment, patients are not recommended to work with dangerous mechanisms and drive vehicles.

Children. There is no experience with the use of the drug in the treatment of children, therefore it is used in pediatric practice.

Simultaneous use with neuroleptics and tranquilizers potentiates, and with central nervous system stimulants – weakens the effect of each component of the drug. Barboval, containing derivatives of barbituric acid, enhances the effect of local anesthetics, analgesics and hypnotics. Alcohol enhances the effects of the drug and may increase its toxicity. The effect of the drug is enhanced against the background of the use of valproic acid preparations. The presence of phenobarbital in Barboval can induce liver enzymes, and this makes its simultaneous use with drugs that are metabolized in the liver undesirable (with coumarin derivatives, griseofulvin, glucocorticoids, oral contraceptives, cardiac glycosides, antimicrobial, antiviral, antifungal, antiepileptic, anticonvulsant, psychotropic, oral hypoglycemic, hormonal, immunosuppressive, cytostatic, antiarrhythmic, antihypertensive drugs, etc.), since their effectiveness will decrease as a result of a higher level of metabolism. MAO inhibitors prolong the effect of phenobarbital. Rifampicin may reduce the effect of phenobarbital.

The risk of kidney damage increases when phenobarbital is used simultaneously with gold preparations.

With prolonged use of phenobarbital with NSAIDs, there is a risk of stomach ulcers and bleeding.

Concomitant use of phenobarbital with zidovudine increases the toxicity of both drugs.

The drug increases the toxicity of methotrexate. Alcoholic beverages should be avoided while taking the drug.

With prolonged or frequent use, cumulation of the drug may occur, leading to clinical manifestations of overdose, namely:

• CNS depression, which is eliminated by the use of CNS stimulants (caffeine, cordiamine, etc.);
• Nystagmus, ataxia, decreased blood pressure, abnormalities in blood count.

Manifestations of chronic bromine poisoning include depression, apathy, rhinitis, conjunctivitis, hemorrhagic diathesis, and impaired coordination of movements. Symptomatic therapy is prescribed to eliminate these manifestations.

Continuous long-term use of the drug can cause addiction, drug dependence, withdrawal syndrome, and sudden cessation of use – withdrawal syndrome. Long-term use of the drug is sometimes accompanied by increased psychodynamic activity instead of the expected sedation.

Symptoms of overdose: respiratory depression, up to its cessation; CNS depression, up to coma; cardiovascular depression, including rhythm disturbances, decreased blood pressure, up to a collaptoid state; nausea, weakness, decreased body temperature, decreased diuresis.

Treatment is symptomatic.

In the original packaging at a temperature not exceeding 25 °C.